Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002,…
Intellia Gets FDA Orphan Drug Status For Hereditary Angioedema Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ: NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE).
NTLA-2002 is currently being evaluated in a Phase 1/2 study in adults with Type I or Type II HAE.
Macy’s, Palo Alto Networks And Other Big Gainers From Tuesday
U.S. stocks closed mostly lower with the Dow Jones dropping more than 150 points on Tuesday. Here is the list of some big stocks moving higher in the previous session.
Intellia Therapeutics To Present Interim Clinical Data From Ongoing Phase 1/2 Study Of NTLA-2002 For Treatment Of Hereditary Angioedema At 2022 Bradykinin Symposium
First clinical data on safety and activity of NTLA-2002, Intellia's second systemically administered in vivo CRISPR candidate
SVB Leerink Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $152
SVB Leerink analyst Mani Foroohar maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and lowers the price target from $155 to $152.
Clorox, Crocs And Some Other Big Stocks Moving Lower On Thursday
AMTD Digital Inc. (NYSE: HKD) dipped 43.6% to $620.00 on possible profit taking after the stock surged over the last few trading days.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Intellia’s Gene-Editing Candidate Shows Durability In ATTR Amyloidosis
Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome…
BMO Initiates Coverage On This Gene Editing Spearhead
BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says…